ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Trifluoroacetic acid → 4-[7-(3-[1,2,4]Triazol-4-yl-propoxy)-quinazolin-4-yl]-piperidine-1-carboxylic acid (6-morpholin-4-yl-pyridin-3-yl)-amide

HRID 657259
印刷

反応式

HRID 657259 の反応式
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([C:14]2[C:23]3[C:18](=[CH:19][C:20]([O:24][CH2:25][CH2:26][CH2:27][N:28]4[CH:32]=[N:31][N:30]=[CH:29]4)=[CH:21][CH:22]=3)[N:17]=[CH:16][N:15]=2)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[C:33](O)([C:35]([F:38])(F)F)=O.[Al].CN(CCO)C.Cl.[N+](C1C=CC(OC(=O)[NH:59][C:60]2[CH:61]=[N:62][C:63]([N:66]3[CH2:71][CH2:70][O:69][CH2:68][CH2:67]3)=[CH:64][CH:65]=2)=CC=1)([O-])=O>C(Cl)(Cl)Cl>[N:66]1([C:63]2[N:62]=[CH:61][C:60]([NH:59][C:6]([N:8]3[CH2:13][CH2:12][CH:11]([C:14]4[C:23]5[C:18](=[CH:19][C:20]([O:24][CH2:25][CH2:26][CH2:27][N:28]6[CH:32]=[N:31][N:30]=[CH:29]6)=[CH:21][CH:22]=5)[N:17]=[CH:16][N:15]=4)[CH2:10][CH2:9]3)=[O:7])=[CH:65][CH:64]=2)[CH2:71][CH2:70][O:69][CH2:68][CH2:67]1.[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([C:14]2[C:23]3[C:18](=[CH:19][C:35]([F:38])=[CH:33][CH:22]=3)[N:17]=[CH:16][N:15]=2)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2]
参加物反応条件実験手順後処理出典と根拠反応ノート

参加物

8

反応物 5

HCID 6422Trifluoroacetic acidHCID 79022-(Dimethylamino)ethanolHCID 5359268AluminumHCID 595517624-[7-(3-[1,2,4]Triazol-4-yl-propoxy)-quinazolin-4-yl]-piperidine-1-carboxylic acid tert-butyl esterHCID 69259253(6-Morpholin-4-yl-pyridin-3-yl)-carbamic acid-4-nitrophenyl ester hydrochloride

生成物 2

HCID 58770718
4-[7-(3-[1,2,4]Triazol-4-yl-propoxy)-quinazolin-4-yl]-piperidine-1-carboxylic acid (6-morpholin-4-yl-pyridin-3-yl)-amide
HCID 595517364-(7-Fluoro-quinazolin-4-yl)-piperidine-1-carboxylic acid tert-butyl ester

試薬・触媒・溶媒 1

HCID 6212Chloroform溶媒

反応条件

温度
40 °C

実験手順

The crude 4-[7-(3-[1,2,4]Triazol-4-yl-propoxy)-quinazolin-4-yl]-piperidine-1-carboxylic acid tert-butyl ester, as prepared in the previous step, was treated with TFA (70 μL) at 100° C. in a sealed vial for 10 min (aluminum block). CHCl3 (450 μL) and DMEA (140 μL, 1.3 mmol) were added, and one-half of the resulting homogeneous amber solution was treated with (6-morpholin-4-yl-pyridin-3-yl)-carbamic acid-4-nitrophenyl ester hydrochloride (22 mg, 58 μmol), as prepared in Example 80a, and stirred at 40° C. for 1.5 hr. (The other one-half of the homogenous solution was diverted to the synthesis given in Example 114.) The reaction was then partitioned with 2M K2CO3 (2 mL) and DCM (2 mL), and the aqueous layer was extracted with 9:1 DCM/MeOH (1×2 mL). The combined organic layers were concentrated and the residue was partially purified with a 5 g silica flash cartridge (97:3 acetone/MeOH eluent with 2% DMEA), and further purified with HPLC (C18 column) to provide the title compound as a powder after lyophilization [2.1 mg, 8.1% overall from 4-(7-fluoro-quinazolin-4-yl)-piperidin-1-carboxylic acid tert-butyl ester.] 1H-NMR (400 MHz, 95:5 CDCl3/CD3OD) δ 9.12 (s, 1H), 8.43 (dd, 1H), 8.30 (br s, 2H), 8.13 (m, 2H), 7.32 (m, 1H), 7.26 (dd, 1H), 6.96 (d, 1H), 4.37 (m, 4H), 4.21 (t, 2H), 3.88 (m, 4H), 3.75 (m, 1H), 3.59 (m, 4H), 3.14 (m, 2H), 2.42 (pentet, 2H), 2.16-1.95 (m, 4H). LC/MS (ESI) calcd mass 543.3, found 544.1 (MH)+.

後処理

  1. customas prepared in Example 80a
  2. custom) The reaction was then partitioned with 2M K2CO3 (2 mL) and DCM (2 mL)
  3. extractionthe aqueous layer was extracted with 9:1 DCM/MeOH (1×2 mL)
  4. concentrationThe combined organic layers were concentrated
  5. customthe residue was partially purified with a 5 g silica flash cartridge (97:3 acetone/MeOH eluent with 2% DMEA)
  6. customfurther purified with HPLC (C18 column)

出典と根拠

ORDレコード
ord-8bee2a3e66ba4845bd52c1ca64defbc7
出典データセット
uspto-grants-2011_12
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08071768B2

反応ノート

このページの内容参加物反応条件実験手順後処理出典と根拠反応ノート